文献速递免疫规划营养与食品安全卫生政策与健康促进

用潜在疫苗减少志贺菌所致线性生长迟缓的长期经济效益预测:一项模型研究

Projecting the long-term economic benefits of reducing Shigella-attributable linear growth faltering with a potential vaccine: a modelling study.
PubMed 文献 · Lancet Glob Health · 2023-01-01

该效益-成本分析在102个中低收入国家建模,评估志贺菌疫苗通过减少线性生长迟缓带来的生产力效益与疫苗项目净成本之比。结果显示所有区域均具成本效益,东南亚区和Gavi资格国效益成本比最高,分别为21.67和14.45,东地中海区最低为2.90。作者建议未来评估肠道感染干预措施的经济健康影响时应考虑线性生长迟缓。

要点

  • 在102个中低收入国家建模,所有区域疫苗项目均显示成本效益。
  • 东南亚区效益成本比21.67,Gavi资格国14.45,东地中海区最低2.90。
  • 将线性生长迟缓减少的生产力效益纳入现有成本效果估计,近所有区域出现长期成本节约。

核心结论

  • 即使采用保守假设,对线性生长迟缓仅中等有效的志贺菌疫苗在某些区域仅凭生产力增益即可收回成本。
  • 作者建议未来评估预防肠道感染干预措施的经济和健康影响模型应考虑线性生长迟缓。
  • 作者指出需进一步研究疫苗对线性生长迟缓的效力以指导此类模型。

研究设计与样本

  • 效益-成本分析,在102个有近期发育迟缓估计、每年至少一例志贺菌所致死亡且有经济数据的中低收入国家建模。
  • 模型仅计算与线性生长改善相关的效益,不包含减少腹泻负担的其他效益。
  • 各国效应量以年龄别身高Z评分(HAZ)变化表示,分别代表预防志贺菌所致较轻腹泻和中重度腹泻的儿童(5岁以下)人群平均变化。
  • 效益数据按国家计算并与疫苗项目估计净成本结合为效益成本比(BCR);BCR高于平价即每1美元成本对应1美元效益被视为成本效益,1.10:1为临界结果。
  • 国家按WHO区域、世界银行收入类别和Gavi疫苗联盟支持资格聚合分析。

主要发现

  • 基准情景下所有区域均显示成本效益,东南亚区BCR为21.67,Gavi资格国为14.45,东地中海区最低为2.90。
  • 除更保守情景(如假设较早退休年龄和较高贴现率)外,所有区域疫苗接种均显示成本效益。
  • 结果对身高增加的假设回报、疫苗对线性生长损害效力的假设、预期HAZ变化和贴现率敏感。
  • 将线性生长迟缓减少的生产力效益纳入现有成本效果估计后,近所有区域出现长期成本节约。

关键数值与推荐

  • BCR高于平价(每1美元成本对应1美元效益,10%边际即1.10:1代表临界结果)被视为成本效益。
  • 基准情景下东南亚区BCR为21.67,Gavi资格国为14.45,东地中海区为2.90。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 结果对身高增加的假设回报、疫苗对线性生长损害效力的假设、预期HAZ变化和贴现率敏感。
  • 更保守情景(如假设较早退休年龄和较高贴现率)下并非所有区域均显示成本效益。
  • 作者指出需进一步研究疫苗对线性生长迟缓的效力以指导此类模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Linear growth is an important outcome of child development with implications for economic productivity. Enteric infections, particularly Shigella, have been linked to linear growth faltering (LGF). However, benefits from potential reductions in LGF are rarely included in economic analyses of enteric infections. We aimed to quantify the economic benefits of vaccination related to reduced Shigella-attributable disease and associated LGF compared with the net costs of a vaccine programme. METHODS: In this benefit-cost analysis, we modelled productivity benefits in 102 low-income and middle-income countries that had recent stunting estimates available, at least one Shigella-attributable death annually, and available economic data, particularly on gross national income and growth rate projections. We modelled benefits strictly related to linear growth improvements and no other benefits associated with reducing diarrhoeal burden. The effect size in each country was calculated as shifts in height-for-age Z score (HAZ), representing population average changes for preventing Shigella-attributable less-severe diarrhoea and moderate-to-severe diarrhoea separately for children younger than 5 years. Benefits data were calculated per country and combined with estimated net costs of the vaccine programme in the form of benefit-cost ratios (BCRs); BCRs above parity, or $1 in benefits per $1 in costs (with a 10% margin representing borderline results: 1·10:1), were considered cost-beneficial. Countries were aggregated for analysis by WHO region, World Bank income category, and eligibility for support from Gavi, the Vaccine Alliance. FINDINGS: In the base-case scenario, all regions exhibited cost-beneficial results, with the South-East Asia region and Gavi-eligible countries exhibiting the highest BCRs (21·67 for the South-East Asia region and 14·45 for Gavi-eligible countries), and the Eastern Mediterranean region yielding the lowest BCRs (2·90). All regions exhibited cost-beneficial results from vaccination, except in more conservative scenarios (eg, those assuming early retirement ages and higher discount rates). Our findings were sensitive to assumed returns for increased height, assumptions about vaccine efficacy against linear growth detriments, the anticipated shift in HAZ, and discount rate. Incorporating the productivity benefits of LGF reduction into existing cost-effectiveness estimates resulted in longer-term cost-savings in nearly all regions. INTERPRETATION: LGF is a secondary outcome of Shigella infection and reduction in LGF is not often quantified as a health or economic benefit of vaccination. However, even under conservative assumptions, a Shigella vaccine only moderately effective against LGF could pay for itself from productivity gains alone in some regions. We recommend that LGF be considered in future models assessing the economic and health impacts of interventions preventing enteric infections. Further research is needed on vaccine efficacy against LGF to inform such models. FUNDING: Bill & Melinda Gates Foundation, Wellcome Trust.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Puett C, Anderson JD, Bagamian KH, et al. Projecting the long-term economic benefits of reducing Shigella-attributable linear growth faltering with a potential vaccine: a modelling study. Lancet Glob Health. 2023. PMID: 37202024. doi:10.1016/S2214-109X(23)00050-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。